Main Objectives

• To develop validated pre-clinical challenge models with increased predictive capacity to support ranking of novel drugs.
• To further test the reproducibility and sensitivity of novel biomarkers that can be used for PK/PD studies.
• To establish mathematical models describing the relationship between drug exposure and biomarker response and the relationship between pre-clinical and clinical studies.

WP Leads

Academic Lead: Dr Fabienne Aujard (CNRS, France)

Industry Lead: Dr Yves Lamberty (UCB)

WP Partners

• University of Lille, France
• University of Murcia, Spain
• CNRS, France
• University of Verona, Italy
• University of Foggia, Italy
• Mario Negri Institute, Italy
• GSK
• Servier
• UCB
• Lilly
• J&J